ArticleNeuroscience letters2025
Evaluating the effects of pro-myelinating drugs on motor function and myelination in a zebrafish model of genetic leukoencephalopathy.
Article in Neuroscience letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Genetic leukoencephalopathy (gLE) is a white matter disorder affecting the central nervous system, causing hypomyelination, developmental delays, motor deterioration, and cognitive, visual, and hearing impairments. Its clinical variability makes diagnosis challenging. A novel homozygous missense mutation, p.Cys846Gly in VACUOLAR PROTEIN SORTING 11 (VPS11), has been linked to infantile-onset gLE in humans. A zebrafish vps11 mutant model was developed to replicate gLE-like hypomyelination and sensorimotor deficits. This study investigates the effects of Clemastine, a pro-myelinating drug, on motor function and myelination in zebrafish larvae with mutations in the vps11 gene. We exposed zebrafish larvae to this drug during a critical period of early nervous system development, from 2 to 4 days post-fertilization (dpf), and assessed visuomotor responses at 7 dpf. Although Clemastine significantly increased the number of oligodendrocytes, it failed to improve visuomotor function in vps11 mutants. These findings imply that increasing oligodendrocyte numbers does not necessarily result in improved behavioral responses in vps11 mutants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.